Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaids-associated ulcers complication

Digestive Endoscopy

Volumn 25, Issue 1, 2013, Pages 25-31

  Miyake, Kazumasa ^a   Kusunoki, Masafumi ^a   Ueki, Nobue ^a   Nagoya, Hiroyuki ^a   Kodaka, Yasuhiro ^a   Shindo, Tomotaka ^a   Kawagoe, Tetsuro ^a   Gudis, Katya ^a   Futagami, Seiji ^a   Tsukui, Taku ^a   Nakamura, Hiroshi ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

antithrombotic agents; bleeding; non steroidal anti inflammatory drugs (NSAIDs); peptic ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BERAPROST; BISPHOSPHONIC ACID DERIVATIVE; CILOSTAZOL; CIMETIDINE; CORTICOSTEROID; DIPYRIDAMOLE; FAMOTIDINE; HEMOGLOBIN; ICOSAPENTAENOIC ACID; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN E1 DERIVATIVE; RABEPRAZOLE; RANITIDINE; SARPOGRELATE; TICLOPIDINE; TRAPIDIL; WARFARIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOSCOPICALLY DETERMINED PEPTIC ULCER; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RHEUMATOID ARTHRITIS;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC AGENTS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; RETROSPECTIVE STUDIES;

EID: 84872047432     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2012.01334.x     Document Type: Article

References (51)

1. Goldstein JL,. Who needs prophylaxis of nonsteroidal antiinflammatory drug-induced ulcers and what is optimal prophylaxis? Eur. J. Gastroenterol. Hepatol. 2000; 12: S11-15.
2. Yuan YH, Wang C, Yuan Y, Hunt RH,. Meta-analysis: Incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials. Aliment. Pharmacol. Ther. 2009; 30: 197-209.
3. Lanas A, Scheiman J,. Low-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatment. Curr. Med. Res. Opin. 2007; 23: 163-173.
4. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
5. Gaskell H, Derry S, Andrew Moore R, et al. Prevalence of anaemia in older persons: Systematic review. BMC Geriatr. 2008; 8: 1-8.
6. Izaks GJ, Westendorp RG, Knook DL,. The definition of anemia in older persons. JAMA 1999; 281: 1714-1717.
7. Chaves PH, Xue QL, Guralnik JM, et al. What constitutes normal hemoglobin concentration in community-dwelling disabled older women? J.Am.Geriatr. Soc. 2004; 52: 1811-1816.
8. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Arch. Intern. Med. 2005; 165: 2214-2220.
9. Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107: 3841-3846.
10. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J. Am. Geriatr. Soc. 2004; 52: 719-724.
11. Semba RD, Guralnik JM, Chaves P, et al. Women's Health and Aging Studies. Iron status and anemia in a populationbased study of women with and without disability living in the community: The Women's Health and Aging Studies. Haematologica 2004; 89: 357-358.
12. Patel KV, Harris TB, Faulhaber M, et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 2007; 109: 4663-4670.
13. Frostegård J., Atherosclerosis in patients with autoimmune disorders. Arterioscler.Thromb.Vasc. Biol. 2005; 25: 1776-1785.
14. Del Rincõn I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 2003; 48: 1833-1840.
15. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity. Ann. Rheum. Dis. 2010; 69: 1920-1925.
16. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
17. Wolfe F, Freundlich B, Straus WL,. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J. Rheumatol. 2003; 30: 36-40.
18. Kimmey MB,. Role of endoscopy in nonsteroidal anti-inflammatory drug clinical trials. Am. J. Med. 1998; 105: 28S-31S.
19. Moore A, Bjarnason I, Cryer B, et al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J. Clin. Gastroenterol. 1995; 21: 103-106.
20. Hawkey CJ,. Non-steroidal anti-inflammatory drug gastropathy: Causes and treatment. Scand. J. Gastroenterol. Suppl. 1996; 220: 124-127.
21. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF,. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis.A prospective observational cohort study. Arch. Intern. Med. 1996; 156: 1530-1536.
22. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 2005; 22: 795-801.
23. Singh G,. Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am. J. Med. 1998; 105: 31S-38.
24. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann. Intern. Med. 1993; 119: 257-262.
25. Weisman SM, Graham DY,. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch. Intern. Med. 2002; 162: 2197-2202.
26. Agrawal NM, Van Kerckhove HE, Erhardt LJ, Geis GS., Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig. Dis. Sci. 1995; 40: 1125-1131.
27. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch. Intern. Med. 1993; 153: 2565-2571.
28. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1996; 334: 1435-1439.
29. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS,. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin. Ther. 1999; 21: 992-1003.
30. Recommendation for the medical management of osteoarthritis of the hip and knee. 2000 update.American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43: 1905-1915.
31. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104: 728-738.
32. Wofe MM, Lichtenstein DR, Singh G,. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1999; 340: 1888-1899.
33. Rostom A, Dube C, Wells G, et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst. Rev. 2002; (4): CD002296.
34. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using nonselective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol. 2006; 101: 701-710.
35. Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP,. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment. Pharmacol. Ther. 2009; 30: 767-774.
36. Tsumura H, Fujita T, Tamura I, et al. Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients. J. Gastroenterol. 2010; 45: 944-951.
37. Tegeder I, Pfeilschifter J, Geisslinger G,. Cyclooxygenase independent actions of cyclooxygenase inhibitors. FASEB J. 2001; 15: 2057-2072.
38. Laine L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM,. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: A controlled double-blind trial. Aliment. Pharmacol. Ther. 1995; 9: 127-135.
39. Tanigawa T, Watanabe T, Higuchi K, et al. Long-term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Helicobacter pylori infection via attenuation of gastric mucosal inflammation. J. Gastroenterol. 2009; 44: 8-17.
40. de Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12: 477-485.
41. Tran H, Anand SS,. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867-1874.
42. Gaskell H, Derry S, Moore RA,. Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review. BMC Geriatr. 2010; 10: 71-77.
43. Kaffes A, Cullen J, Mitchell H, et al. Effect of Helicobacter pylori infection and low-dose aspirin use on iron stores in the elderly. J. Gastroenterol. Hepatol. 2003; 18: 1024-1028.
44. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-2420.
45. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003; 108: 1682-1687.
46. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.
47. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005; 294: 1224-1232.
48. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK,. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
49. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
50. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ 2006; 333: 726-730.
51. Thein M, Ershler WB, Artz AS, et al. Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore) 2009; 88: 107-114.